Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Anavex Life Sciences Corp. (AVXL)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | Benzinga
2 weeks ago | Zacks Investment Research
a month ago | Benzinga
a month ago | Pulse2
a month ago | Benzinga
a month ago | The Motley Fool
a month ago | Benzinga
a month ago | GlobeNewsWire